Indian stocks: Visit www.stage2stocks.com →

Satellos Bioscience Inc.

Stage 3 · Topping · week 3

As of Oct 22, 2026, Satellos Bioscience is in Stage 3, the topping phase, now in week 3 (since Oct 8, 2026). It closed at $6.63, 49.1% below its 52-week high and below its 200-day average, which is rising.

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. More about the company

$6.63
-1.12% today
$141M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is MSLE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 15w
S3 15w
S4 16w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 7w → S4 10w → S1 8w → S2 10w → S3 7w → S4 2w → S2 8w → S3 1w → S4 7w → S1 1w → S2 15w → S3 15w → S4 16w → S1 7w → S2 8w → S3 4w → S2 11w → S3 6w → S4 7w → S1 4w → S2 9w → S3 2w current
Total tracked: 165 weeks across 22 stage runs.

MSLE among Biotechnology172nd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…172MSLEStage 3 · wk 358−21.2%
vs 52W High
-49.1%
$5.59 lo$13.01 hi
49.1% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 3
1w13w26w
Week 3, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-22.1%
200 DMA: $8.50 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.48x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-21.2%
3M
-32.3%
6M
-2.7%
YTD
+6.8%
1Y
+4.2%
Scan Membership
Breakout Watch
Latest: 2024-10-18
9 appearances in last 60 days. First seen: 2019-05-02.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 3 · Vol 0.48x
2026-10-21S3
Wk 2 · Vol 0.63x
2026-10-20S3
Wk 2 · Vol 0.31x
2026-10-19S3
Wk 2 · Vol 0.67x
2026-10-16S3
Wk 2 · Vol 0.30x
2026-10-15S3
Wk 2 · Vol 1.86x
2026-10-14S3
Wk 1 · Vol 1.02x
2026-10-13S3
Wk 1 · Vol 2.20x
2026-10-12S3
Wk 1 · Vol 1.59x
2026-10-09S3
Wk 1 · Vol 1.48x
2026-10-08S32→3
Wk 1 · Vol 3.13x
2026-10-07S2
Wk 9 · Vol 1.24x
Moving averages & range
50 DMA
$8.67
200 DMA
$8.50
52W High
$13.01
52W Low
$5.59
5D Low
$6.44
Resistance levels (recent highs)
20d High
$8.81
60d High
$10.19
120d High
$10.19
250d High
$13.01
Next resistance
+33.0%
to 20d High
ROE
-70.4%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 2.3

Satellos Bioscience: quick answers

What stage is Satellos Bioscience in?

As of Oct 22, 2026, Satellos Bioscience (MSLE) is in Stage 3, the topping phase. It entered Stage 3 on Oct 8, 2026 and is in week 3. What the four stages mean

Is Satellos Bioscience in an uptrend?

Its uptrend has stalled. Satellos Bioscience is in Stage 3, the topping phase that follows an advance. It trades 22.1% below its 200-day average, which is rising.

How far is Satellos Bioscience from its 52-week high?

Satellos Bioscience closed at $6.63 on Oct 22, 2026, 49.1% below its 52-week high of $13.01. Its 52-week low is $5.59.

How has Satellos Bioscience performed over the past year?

As of Oct 22, 2026, Satellos Bioscience is up 4.2% over the past year and up 6.8% so far in 2026.

Which sector and industry is Satellos Bioscience in?

Satellos Bioscience is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.